Additive manufacturing (AM), which
includes the 3-D printing process, may
prove to be a game changer for biopharma
as 3-D printing becomes widespread.
The AM process covers a range of categories
defined by the American Society for
Testing and Materials (ASTM) such as
VAT photo-polymerization, binder jetting,
material jetting, material extrusion,
powder bed fusion, sheet lamination and
directed energy deposition (1).